Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Operational Other
confidence 72%
filed 2026-07-15
The filing discloses the completion of the EMJX acquisition and announcement of paper-traded EMJX returns of 26% since February 11, 2026, along with a fireside chat discussing the company's new AI-enabled investment platform strategy. While the acquisition itself (a material M&A event) is mentioned as recently closed, the primary disclosure focus in this 8-K is on operational and strategic positioning—the company's new business model combining operating expertise with proprietary AI for multi-asset treasury management. The Item 7.01 classification and emphasis on the EMJX strategy, performance metrics, and forward-looking platform positioning indicate this is primarily an operational/strategic disclosure rather than a discrete M&A transaction announcement.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-15
The filing discloses positive preclinical results for Azitra's ATR-COSF cosmetic program, demonstrating improved skin penetration and elasticity in ex vivo human skin studies. This represents a material operational/product development milestone for a clinical-stage biopharmaceutical company, advancing toward human trials. While not fitting a specific named event type, the disclosure of significant scientific progress on a key product candidate would affect a reasonable investor's assessment of the company's pipeline and commercial prospects.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-15
Jeffrey Millard, Chief Operating Officer, resigned effective July 10, 2026. Item 5.02 discloses the departure of a named officer, making this a clear executive departure event. The COO role is material to the company's operations and governance.
View raw filing on EDGAR →
8-K
Going Concern
confidence 75%
filed 2026-07-15
The filing discloses in Item 4.01 that the prior auditor's (BCRG's) audit reports for fiscal years ended September 30, 2025 and 2024 "included an explanatory paragraph indicating that there was substantial doubt as to the Company's ability to continue as a going concern." This is a material disclosure of going-concern uncertainty that would significantly affect a reasonable investor's assessment of the registrant's viability.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-15
AST SpaceMobile announced a proposed private offering of $1.0 billion of convertible senior notes due 2034, with an additional $150 million option. The filing discloses the company's intent to enter into capped call transactions and describes the terms, use of proceeds, and mechanics of the convertible debt offering. This is a material creation of a new direct financial obligation under Item 2.02 and Item 8.01.
View raw filing on EDGAR →
6-K
M&A activity
confidence 98%
filed 2026-07-15
The 6-K discloses entry into an Agreement and Plan of Merger dated July 14, 2026, whereby GrowHub Limited will acquire EnChem America, Inc. (a wholly-owned subsidiary of EnChem Co., Ltd.) for approximately $400 million in equity consideration (142,848,176 Class A ordinary shares representing 85% of fully-diluted shares post-closing). This is a material acquisition transaction requiring disclosure under Item 1.01 of Form 8-K (or equivalent 6-K disclosure). The transaction is subject to customary closing conditions including SEC registration statement effectiveness and NASDAQ listing approval.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 95%
filed 2026-07-15
The filing discloses the resignation of Liebman Hymowitz, LLP as the Company's independent registered public accounting firm effective July 13, 2026, and the appointment of Vilki & Co., Charted Accountants as the new auditor effective July 15, 2026. This is a classic auditor change under Item 4.01. The materiality is heightened by the fact that the departing auditor's report included an explanatory paragraph regarding substantial doubt about the Company's ability to continue as a going concern, signaling underlying financial stress.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-15
The filing discloses completion of an acquisition of approximately 290,000 square meters of land in Spain designated for the JP Financial Arena development. The press release explicitly states "Nomadar Corp. today announced that it has completed the acquisition" and describes this as consolidating "control over a strategic asset" that "strengthens the Company's ability to advance the development of JP Financial Arena." This is a material acquisition of a real estate asset central to the company's strategic platform.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-15
On July 15, 2026, Taoping Inc. entered into a Securities Purchase Agreement with Streeterville Capital, LLC to issue an unsecured convertible promissory note with a principal amount of $3,195,000. The Convertible Note is convertible into up to 2,970,440 ordinary shares at a conversion price of $6.00 per share, with the investor able to convert all or any portion of the outstanding balance. This is a classic dilutive issuance of equity securities through a convertible debt instrument, raising approximately $3.0 million in net proceeds for working capital and general corporate purposes.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-07-15
PHP Ventures Acquisition Corp., a SPAC, disclosed under Item 8.01 that it deposited $957.30 into its trust account to extend the deadline for completing an initial business combination by one month (from July 16, 2026 to August 16, 2026). This is a material event for a SPAC investor as it directly affects the timeline and likelihood of deal completion, but it does not fit neatly into standard event categories—it is neither a completed M&A transaction, a going-concern issue, nor a routine governance matter. The company was already suspended from Nasdaq trading as of April 2024, adding urgency to the extension.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-15
EX-99.1
This press release announces the unveiling of CORE, a major new operating environment and trade execution engine that is described as "the final foundational enabling technology" of RedCloud's RedAI infrastructure, with an anticipated August 2026 launch. The announcement discloses a significant product milestone and strategic capability expansion (pairing CORE with RAID to enable autonomous trade execution), which would materially affect a reasonable investor's assessment of the company's product roadmap and competitive positioning. While not a discrete M&A, financing, or governance event, this is a material operational and strategic disclosure of a major technology release that the company positions as transformative to its business model.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-15
The 6-K discloses the appointment of three executives effective July 13, 2026: Ms. Chen Shulan as Executive Chairman and Director (with US$300,000 annual base compensation), Ms. Lim Hui Leng as independent Director and Audit Committee Chairman (US$20,000 annual fee), and Mr. Yuen Jia Feng Leonard as Chief Financial Officer (SGD 10,500 monthly salary). These are material leadership changes affecting the registrant's governance and financial oversight structure.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-15
Item 8.01
The Item 8.01 disclosure describes the completion of a strategic business combination between Glucotrack, Inc. and Lōkahi Therapeutics, with Lōkahi becoming the operating and controlling business of the combined company. The press release (Exhibit 99.1) explicitly states "Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination" and references an Agreement and Plan of Merger dated July 14, 2026 (Exhibit 2.1). This is a material acquisition/change of control transaction that fundamentally restructures the company's ownership and operations.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-07-15
The filing discloses compensatory arrangements for three named executives: (1) a discretionary equity award of 50,000 RSUs to the Chief Operating Officer (Amaree Vichairattanawong), fully vested on grant date July 10, 2026; and (2) option awards to CEO Justin Kenna (1,045,712 shares) and CFO Michael Munoz (301,249 shares), both granted July 10, 2026 with 62.5% vesting immediately and 37.5% vesting one year later. The Item 5.02(e) disclosure centers on these equity grants and compensatory arrangements rather than any departure or appointment.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-15
The filing discloses completion of Stereotaxis's acquisition of Robocath on July 7, 2026, pursuant to a Share Sale Agreement dated April 14, 2026. The company issued 6,269,628 closing shares and is obligated to pay up to $25 million in earnout consideration upon achievement of regulatory and commercial milestones. This is a material acquisition of 100% of Robocath's share capital and voting power, disclosed under Item 8.01 (Other Events), with extensive risk factors and transaction documents incorporated by reference.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-15
Global AI, Inc. entered into a Subscription Agreement on July 9, 2026, to sell 250,000 shares of Class A common stock to KSY Capital Investments, Inc. for $500,000 ($2.00 per share). The filing explicitly discloses this under Item 1.01 (Entry into a Material Definitive Agreement) and Item 3.02 (Unregistered Sales of Equity Securities), confirming an unregistered private placement made pursuant to Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D. This is a dilutive equity issuance that would materially affect a reasonable investor's assessment of ownership dilution and capital structure.
View raw filing on EDGAR →
8-K
Workforce Reduction
confidence 95%
filed 2026-07-15
Item 2.05
Sprout Social announced a Board-approved workforce reduction affecting approximately 260 employees (20% of workforce) with estimated pre-tax restructuring charges of $18.0–$20.0 million. The reduction includes severance (12 weeks salary plus tenure-based increments), six months of healthcare coverage, equity acceleration, and outplacement support, with charges expected to be recognized in Q3 2026.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 85%
filed 2026-07-15
Item 8.01
The Board approved an expansion of the share repurchase program from $50 million to $100 million authorization. Share repurchase programs are a form of capital return to shareholders and fall within the dividend_distribution category, which encompasses "share-repurchase programs" alongside dividends and distributions. The doubling of authorization is material to investors assessing capital allocation and shareholder returns.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-07-15
Item 7.01
The filing announces a scheduled earnings release and conference call to discuss Q2 2026 financial results for the period ended June 30, 2026. The press release explicitly states "Carlyle Secured Lending, Inc. Schedules Earnings Release and Quarterly Earnings Call to Discuss its Financial Results for the Second Quarter Ended June 30, 2026" and confirms the Company will report quarterly financial results on August 6, 2026. This is a material disclosure of upcoming earnings announcement, which affects investor assessment of the registrant's financial performance.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 85%
filed 2026-07-15
Item 8.01
News Corporation discloses daily share repurchase activity under its authorized $1 billion repurchase program, with specific transactions totaling approximately $238.5 million in Class A and Class B stock purchases on July 15–16, 2026. Share repurchases constitute a return of capital to shareholders and are classified as dividend_distribution events. The company has spent approximately $367 million of the $1 billion authorization to date, making this an ongoing material capital allocation activity.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-15
EX-99.1
This exhibit is a conference call transcript disclosing a material manufacturing and supply issue with semaglutide, a key product. Dr. Reddy's identified an out-of-specification impurity in the scaled-up API manufacturing process, requiring a halt to commercial supplies for approximately three months (until late October/early November 2026) while validation is repeated. The CEO explicitly states this will result in a temporary delay to commercial supplies and a write-down of inventory at OneSource. This is a material operational/supply disruption affecting a major product, though it does not fit neatly into the specific event categories (not a restatement, impairment charge, or workforce reduction per se, but rather a manufacturing/quality issue with supply consequences). The domain is clearly operational rather than financial, governance, legal, or existential.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-07-15
Item 7.01
The Board declared an irregular cash dividend of $1.00 per share, returning approximately $42.8 million to shareholders, payable August 12, 2026.
View raw filing on EDGAR →
8-K
Financial Other
confidence 72%
filed 2026-07-15
Item 8.01
The company completed the sale of the VLGC Corsair vessel for $81.8 million in net proceeds, a material disposition of a vessel asset.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-07-15
Item 2.02
PNC issued a press release on July 15, 2026 disclosing second quarter 2026 financial results, including net income of $2.1 billion and diluted EPS of $4.81 ($4.85 as adjusted). The filing explicitly states "PNC issued a press release regarding PNC's earnings and business results for the second quarter of 2026" with the press release attached as Exhibit 99.1. This is a standard quarterly earnings release disclosure under Item 2.02.
View raw filing on EDGAR →
8-K
M&A activity
confidence 96%
filed 2026-07-15
Item 1.01
Senti Biosciences entered into an Agreement and Plan of Merger on July 14, 2026, whereby a newly formed company controlled by Celadon Partners will acquire substantially all of the company's Gene-Circuit-enabled pipeline assets (including SENTI-202) in exchange for a contingent value right with up to $60 million in milestone payments. The transaction constitutes a material change of control, with Celadon beneficially owning 54.6% to 77.5% of the company's common stock post-closing, and requires stockholder approval.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-07-15
Item 2.02
Eos Energy Enterprises announced preliminary financial results for Q2 2026, including record quarterly revenue of $68–69 million, gross margin loss of 69–73%, record backlog of approximately $807 million, and cash position of approximately $364 million. A conference call to discuss full results is scheduled for August 5, 2026.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-15
EX-99.1
This press release discloses material progress on the Boumadine Project's feasibility study and updated preliminary economic assessment, including infill drilling completion (102,111m year-to-date), advancement of procurement and contractor tender processes, water supply and power infrastructure engineering, and metallurgical testwork. The company announces the Updated PEA will be released in H2-2026 and feasibility study completion targeted for H2-2027, with plans to commence early works by year-end. These are significant operational and strategic milestones for a major development project that would affect a reasonable investor's assessment of the company's growth prospects and project de-risking.
View raw filing on EDGAR →
8-K
Financial Other
confidence 85%
filed 2026-07-15
Item 8.01
The filing discloses the Company's Net Asset Value (NAV) per share as of June 30, 2026, broken down by share class (Class J at $20.1637 and Class E at $20.2802), along with a detailed NAV calculation showing major asset and liability components totaling $144.3 million. This is a periodic financial disclosure material to investors in a closed-end fund structure, but does not fit the specific categories of earnings_release (no income statement results), material_impairment, or other named financial event types. It is classified as financial_other because it is clearly a financial disclosure of significant importance to shareholders assessing the fund's value, yet falls outside the defined taxonomy.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-15
The 6-K furnishes a press release announcing the availability of an investor presentation by the CEO on the company's "Vision 2028 capital projects update," including updates on a new capital project at Far West Gold Recoveries' Driefontein 2 plant, commissioning timelines, and revised capital forecasts. This is an operational/strategic disclosure of material capital project developments and revised forecasts that would affect a reasonable investor's assessment of the company's capital allocation and project execution, but does not fit a more specific event category (not M&A, not a financial restatement, not a workforce action, etc.).
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-15
The exhibit discloses the appointment of Mr Mark Hoffman as an independent non-executive director of DRDGOLD effective August 1, 2026. This is a clear executive/board appointment requiring disclosure under JSE Listings Requirements paragraph 6.71(a). The appointment of a director with significant professional credentials (Chartered Accountant, 35+ years in professional services, former Deloitte and KPMG partner) is material to investors' assessment of board composition and governance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-07-15
Item 7.01
PNC held an investor conference call on July 15, 2026 to discuss second quarter 2026 earnings and business results, providing electronic presentation slides (Exhibit 99.1) that disclose detailed financial results including net income of $2.1 billion, diluted EPS of $4.81, loan growth, revenue metrics, and full-year and quarterly guidance. This is a classic earnings release disclosure under Item 7.01 (Regulation FD Disclosure), with the earnings presentation slides furnished as supporting exhibits.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-15
Item 8.01
Crescent Biopharma entered into an underwriting agreement on July 14, 2026 to issue 8,094,793 ordinary shares at $14.50 per share plus 525,897 pre-funded warrants, with expected net proceeds of approximately $115.9 million (or $133.5 million if the underwriters' 30-day option is exercised in full). This is a registered public offering of equity securities that will dilute existing shareholders. The filing explicitly discloses the offering price, number of shares, and use of proceeds to fund operations into the second half of 2028, making this a material capital-raising event typical of dilutive equity issuances.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 98%
filed 2026-07-15
The 6-K body is a news release announcing that Methanex's Board of Directors has declared a quarterly cash dividend of US$0.185 per share, payable September 30, 2026, to shareholders of record on September 16, 2026. This is a straightforward dividend declaration that would be material to investors assessing the company's capital allocation and shareholder returns.
View raw filing on EDGAR →
8-K
Bankruptcy Filing
confidence 99%
filed 2026-07-15
Item 1.03
Inotiv's Chapter 11 plan of reorganization was confirmed by the U.S. Bankruptcy Court for the Southern District of Texas on July 14, 2026, following the company's voluntary petition filing on June 3, 2026. All outstanding common shares will be canceled and existing equity holders will receive no distribution, with the company expected to emerge as a private entity with a restructured capital structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-15
Item 5.02
The filing discloses the appointment of John Markels to the Board as a Class II director effective July 16, 2026, with concurrent appointment to the Audit Committee and Compensation Committee. While the section also mentions Heath Lukatch's retirement, the principal disclosed action centers on the new director appointment and his committee assignments. Board composition changes are material to investors assessing governance and oversight.
View raw filing on EDGAR →
8-K
Restatement
confidence 98%
filed 2026-07-15
Item 4.02
BayFirst Financial restated consolidated financial statements for years ended December 31, 2024 and 2025, and Q1 2026, due to material understatement of provision expense and overstatement of net interest income. The restatement identified $2.8 million in deferred origination costs and $2.1 million in accrued interest related to defaulted loans, resulting in corrections to 2024 net income (from $12.6M to $11.4M), 2025 net loss (from $22.9M to $24.2M), and Q1 2026 net loss (from $5.7M to $5.9M).
View raw filing on EDGAR →
6-K
M&A activity
confidence 99%
filed 2026-07-15
GSK announces completion of its acquisition of Nuvalent, Inc., a clinical-stage biopharmaceutical company, for approximately $10.6 billion in aggregate equity value (net $9.4 billion). The announcement explicitly states "GSK completes acquisition of Nuvalent, Inc." and describes the transaction as adding three lung cancer assets to GSK's oncology portfolio, including two assets with FDA Breakthrough Therapy designations and expected 2026 launches with "multi-blockbuster potential." This is a material acquisition completion disclosing a substantial change of control and strategic expansion.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 85%
filed 2026-07-15
Item 5.02
The disclosure centers on the Compensation Committee's amendment to the 2026 Inducement Stock Plan, reducing authorized shares from 2,000,000 to 1,538,000. This is a compensatory arrangement amendment affecting equity grants available for new and returning employees, which falls squarely within exec_compensation under Item 5.02(e). While the amendment reduces rather than expands the pool, it materially affects the compensation framework and equity incentive structure available to officers and employees.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-07-15
EX-99.1
This is a notification of a major shareholding change under AIM Rules for Companies. BlackRock, Inc. crossed a notifiable threshold on July 13, 2026, increasing its total voting rights from 6.17% to 6.22% (1,203,763 voting rights). While the change is modest in percentage terms, the disclosure of a major shareholder crossing a regulatory threshold is a governance event material to investors assessing control and influence over the company. This is not a specific named event type (not an appointment, departure, or compensation matter) but clearly a governance-related disclosure that would affect a reasonable investor's assessment of shareholding structure.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-07-15
Item 8.01
iPower announced plans to evaluate expansion into AI infrastructure hardware, including potential acquisition or financing of AI compute hardware and data center relationships. This is a strategic business initiative at the exploratory stage that could materially affect the company's future direction and capital deployment. While no definitive agreements have been entered, the announcement of a planned evaluation into a new sector represents a material operational/strategic development that would affect a reasonable investor's assessment of the company's growth prospects and business strategy.
View raw filing on EDGAR →
8-K
Restatement
confidence 99%
filed 2026-07-15
Item 4.02
The filing explicitly discloses that the Company's independent auditor advised that previously issued financial statements "should no longer be relied upon" due to errors in accounting for defaults on certain loans payable. The Company identified material errors totaling $1,376,890 in three quarterly periods (Q1, Q2, Q3 2025) that resulted in understated current portion of loans payable and unrecorded non-operating losses. The Company concluded these errors were material under FASB ASC 250, SAB No. 99, and SAB No. 108, and intends to file amended Form 10-Q/A filings to restate the affected financial statements. This is a classic financial restatement disclosure under Item 4.02.
View raw filing on EDGAR →
8-K
Financial Other
confidence 72%
filed 2026-07-15
Item 8.01
Edgemode entered into a leakout agreement with lenders holding approximately $1.6 million in convertible promissory notes, restricting conversion and transfer rights to 30% (or 15% if stock falls below $0.003) per 30-day period through December 31, 2026. This is a material financial arrangement affecting the company's capital structure and dilution risk, but does not fit the specific categories of debt_issuance (no new debt created), dilutive_issuance (no new equity issued), or covenant_breach (a protective agreement, not a violation). The leakout agreement is a financial obligation management tool that would affect investor assessment of dilution risk and is best classified as a financial event outside the named categories.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-15
Item 1.01
International Stem Cell Corporation entered into a Membership Interest Purchase Agreement on July 10, 2026, to sell 100% of Lifeline Cell Technology, LLC to American Type Culture Collection, Inc. for $25.0 million. This is a material disposition of a subsidiary representing a significant asset sale, with customary closing conditions and stockholder approval requirements, clearly constituting a material M&A transaction under Item 1.01.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-15
Item 3.02
The filing discloses an unregistered private placement of preferred stock under Rule 506(b) of Regulation D, with 171,077 shares of Series 2025 Preferred Stock sold during the reporting period for approximately $1.7 million in aggregate proceeds. This is a classic dilutive equity issuance to accredited investors without registration, which is material to investors assessing the company's capital structure and ownership dilution.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-15
EX-99.1
BioHarvest announced receipt of a $1.4 million non-dilutive grant from the Israel Innovation Authority to fund a research initiative integrating AI and machine learning into its plant-cell synthesis development workflows. This is a material operational and strategic event—the grant supports core R&D capabilities and represents the company's second IIA grant this year—but does not fit the specific categories of debt issuance, equity dilution, or M&A activity. The funding is non-dilutive and structured as a zero-interest loan contingent on commercial milestones, making it a significant operational development rather than a financial obligation or capital raise.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-15
EX-99.1
BioHarvest announced receipt of a USD $1.4 million non-dilutive grant from the Israel Innovation Authority to fund a research initiative integrating AI, machine learning, and digital sensing into plant cell culture development. This is a material operational and strategic event—the grant funds a significant R&D program that accelerates the company's technological transformation—but does not fit neatly into a specific category (not debt issuance, not equity dilution, not a discrete M&A event). The non-dilutive nature and focus on R&D advancement make `operational_other` the best fit, as it represents a material strategic partnership and funding milestone that would affect a reasonable investor's assessment of the company's R&D capabilities and competitive position.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-07-15
EX-99.2
Electrovaya issued 13,880,345 warrants to Amazon.com NV Investment Holdings LLC, exercisable at US$8.56 per share for ten years, with vesting tied to cumulative purchases of up to US$280 million. The warrant issuance constitutes a material dilutive equity transaction with a strategic investor that will materially affect shareholder ownership and voting power upon exercise.
View raw filing on EDGAR →
8-K
Bankruptcy Filing
confidence 95%
filed 2026-07-15
Lipella Pharmaceuticals filed a voluntary Chapter 11 petition on March 30, 2026, and subsequently entered into an Asset Purchase Agreement with XRAIY on May 14, 2026, approved by the Bankruptcy Court on June 4, 2026. The filing discloses the bankruptcy case number (26-20879-CMB) and the sale of substantially all company assets under Section 363 of the Bankruptcy Code, which is a terminal event materially threatening the registrant's continued existence as an independent entity.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-15
EX-99.1
This exhibit is a press release announcing drill results from Scorpio Gold's Phase Two exploration program at the Manhattan District Project in Nevada. The disclosure reports assay results from 18 drill holes with significant gold intercepts, including the headline result of "2.05 g/t gold over 97.99 metres" from hole 26MN-110 at the Goldwedge target. The company emphasizes the "district-scale potential" and consistent high-grade mineralization across multiple targets (Zanzibar Trend, Goldwedge, Black Mammoth). This is a material operational/exploration milestone that would affect a reasonable investor's assessment of the company's mineral resource development progress and the viability of the Manhattan property.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-07-15
Item 8.01
Veradermics announced positive Phase 2 clinical trial results for VDPHL01 in female pattern hair loss, demonstrating efficacy (88.9–90.0% of patients reporting improvement at Month 6) with rapid onset and a favorable safety profile including no treatment-related serious adverse events. This material clinical milestone supports advancement toward the Phase 2/3 registration trial (Study '306') with topline data anticipated in 1H 2027.
View raw filing on EDGAR →